Analysis of the immune response in vaccinators of the COVID-19 replicon vaccine (corresponding to the JN.1 strain).

Analysis of safety, efficacy and immune response in vaccinees of mRNA vaccine and replicon vaccine (corresponding to JN.1 strain) against COVID-19.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1031240710

Enrollment

Registered

2025-02-28

Start date

2025-02-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1, Men and women aged 20 and over. 2, Persons for whom written consent can be obtained from the person concerned or a proxy or other person 3, Persons eligible for vaccination with COVID-19 vaccine (corresponding to JN.1 strain)

Exclusion criteria

Exclusion criteria: Those who are considered unsuitable by a doctor.

Design outcomes

Primary

Measure	Time frame
The aim is to comprehensively analyse the antibodies induced by vaccination with the JN.1 strain-compatible COVID-19 vaccine and immune cells, to study the efficacy of each vaccine, to study adverse reactions and adverse events, and to identify correlating factors.	—

Secondary

Measure	Time frame
Safety and efficacy of mRNA and replicon vaccines against COVID-19 (corresponding to JN.1 strain) in vaccinees.	—

Contacts

Public ContactMasaharu Shinkai

Tokyo Shinagawa Hospital Social Medical Corporation Association Tokyokyojuno-kai

m.shinkai@tokyo-shinagawa.jp+81-3-3764-0511

Outcome results